At AACR 2025, zongertinib showed promising results in HER2-mutant NSCLC with high response rates, durable control, and a ...

New research uncovers key factors driving survival and treatment response in patients with HER2-positive breast cancer ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

Zongertinib, an oral HER2-selective inhibitor, produced a 71% objective response rate, a median response duration of 14.1 months, and progression-free survival of 12.4 months in previously treated ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...